Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The response content provided is entirely focused on label-supported statements from FYCOMPA prescribing information regarding serious psychiatric/behavioral reactions (hostility/aggression/anger), monitoring, alcohol avoidance, and counseling. No contradictions to the supplied label text are present.
Category Scores
Accurate Statements
FYCOMPA increases risk of serious psychiatric and behavioral reactions, specifically hostility/aggression-related adverse reactions (including anger and related neuropsychiatric events) occurring more frequently than placebo and being dose-related.
Label 5.1 (hostility- and aggression-related adverse reactions occurred 12%/20% at 8/12 mg vs 6% placebo; dose-related; generally appeared within first 6 weeks; serious/severe and led to dose reduction/interruption/discontinuation more often than placebo).
Neuropsychiatric events such as irritability, aggression, anger, anxiety, belligerence, affect lability, agitation, and physical assault occurred in ≥2% of FYCOMPA-treated patients and at least twice as frequently as placebo; some were serious/life-threatening.
Label 5.1 (neuropsychiatric events listed; occurred in 2% or greater and twice as frequently as placebo; some reported as serious and life-threatening).
Homicidal ideation and/or threat occurred in 0.1% of 4,368 FYCOMPA-treated patients in controlled and open label trials and has also been reported postmarketing.
Label 5.1 (0.1% of 4,368; also reported postmarketing).
Patients should avoid alcohol because the combination of alcohol and FYCOMPA significantly worsens mood and increases anger.
Label 5.1 (patients should avoid alcohol; combination significantly worsened mood and increased anger) and Label 7.3 (concomitant use may increase CNS depression; enhanced effects of alcohol include increased anger, confusion, and depression; care should be taken).
Patients/caregivers should monitor for emergence of anger, aggression, hostility, hallucinations, delusions, confusion, unusual changes in mood/personality/behavior, and report symptoms immediately.
Label 17 (counsel to monitor and report immediately) and Label 5.1 (monitor during treatment and for at least 1 month after last dose; reduce dose if symptoms occur; permanently discontinue for persistent severe or worsening psychiatric symptoms/behaviors).
The labeling supports that psychiatric/behavioral reactions can require dose reduction and may lead to discontinuation for persistent severe or worsening symptoms.
Label 5.1 (dose reduced if symptoms occur; permanently discontinue for persistent severe or worsening psychiatric symptoms or behaviors; refer for psychiatric evaluation).
Unsupported Statements
Contradictions
Important Omissions
No explicit mention (in the provided response content) of the label’s specific monitoring duration/interval: monitoring during treatment and for at least 1 month after the last dose, with heightened attention during titration/initial weeks and during dose increases.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response aligns with label warnings and counseling about psychiatric/behavioral reactions and alcohol interaction; it does not introduce off-label use, incorrect contraindications, or dosing instructions.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omission of the label’s specific follow-up monitoring timeframe (at least 1 month after last dose) and titration/dose-increase emphasis.
Suggested Improvement
Add that patients should be monitored during treatment and for at least 1 month after the last dose, especially during the initial few weeks/titration and when increasing the dose, per label section 5.1.